Related Experiment Video
Updated: Jul 25, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study
C H Smith1, K Jackson, S J Bashir
1Skin Therapy Research Unit, St John's Institute of Dermatology, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. catherine.smith@kcl.ac.uk
The British Journal of Dermatology
|June 24, 2006
Summary
Infliximab effectively treats severe, treatment-resistant psoriasis, with most patients showing significant improvement. However, about 25% discontinued treatment due to serious adverse effects, necessitating careful monitoring.
Area of Science:
- Immunodermatology
- Rheumatology
- Pharmacology
Background:
- Infliximab, a TNF-alpha inhibitor, shows efficacy in moderate-to-severe psoriasis.
- Limited data exist on its use in treatment-resistant psoriasis or combination therapies.
Purpose of the Study:
- Evaluate infliximab's effectiveness and safety in severe, recalcitrant psoriasis patients.
- Assess outcomes in a tertiary referral setting.
Main Methods:
- Prospective, open-label study of 23 severe psoriasis patients treated with infliximab (2002-2005).
- Disease severity assessed using PASI and DLQI.
- Adverse events and clinical course were meticulously recorded.
Main Results:
- 95% of patients achieved at least 50% PASI improvement by week 10.
- Sustained efficacy observed in long-term responders.
- 25% discontinued therapy due to serious adverse events, including infections and infusion reactions.
Conclusions:
- Infliximab offers rapid efficacy for severe, treatment-resistant psoriasis.
- Significant adverse events necessitate ongoing pharmacovigilance and further studies.
- Risk-benefit profile requires careful consideration in this patient population.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...